Last Updated: November 16, 2026

Details for Patent: 8,846,649

« Back to Dashboard


Summary for Patent: 8,846,649
Title:Natural combination hormone replacement formulations and therapies
Abstract:Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Inventor(s):Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Assignee: TherapeuticsMD Inc
Application Number:US14/099,571
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,846,649
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

US Patent 8,846,649 (Estradiol solubilized with short-chain triglyceride esters + suspended progesterone): claim scope, enforceable boundaries, and US patent landscape

US Patent 8,846,649 claims a specific combined hormone replacement therapy (HRT) oral formulation: solubilized estradiol plus suspended progesterone in a fatty-acid ester lipid solubilizer (mono-, di-, and triglycerides of C6-C12 fatty acids), with defined solubilization performance (≥90% estradiol solubilized) and physical stability (estradiol not precipitating for ≥14 days in a dependent claim). The claim set also includes method-of-use for treating menopause symptoms in women with a uterus, and multiple dependent limits tying dose strengths, progesterone:estradiol ratios, and a gelatin capsule dosage form.

Below is a claim-by-claim scope teardown, key claim-limiting terms that control infringement and validity, and how this patent fits into the broader US estradiol/progesterone formulation and combination-drug exclusivity landscape.


What is US Patent 8,846,649 claiming in plain claim-language?

Core independent claim (claim 1) covers a pharmaceutical composition with these required elements:

  1. Composition components

    • Estradiol is solubilized (not merely dispersed).
    • Progesterone is suspended (not solubilized, in claim 1 as written).
    • Both are present in the solubilizing agent and are uniformly dispersed.
  2. Performance/acceptance criteria

    • At least about 90% of estradiol is solubilized in the solubilizing agent.
  3. Solubilizer chemical definition

    • Solubilizing agent comprises an effective amount of at least one of mono-, di-, and triglycerides containing an ester of a C6-C12 fatty acid.

Dependent claim 6 tightens scope by adding a stability requirement for estradiol:

  • Estradiol does not precipitate for at least 14 days.

Independent/method coverage (claim 11) mirrors the composition limitations but changes the claimed subject matter to a method of treating menopause symptoms in women with a uterus via administration of the composition.


How broad is claim 1: what exactly must be present for infringement?

Claim 1 is narrow on formulation chemistry and performance. It is not a generic “estradiol/progesterone capsules in oil” claim. It requires all of the following at once:

1) “Solubilized estradiol” is a functional limitation with an objective endpoint

  • The claim quantifies the functional condition: ≥ about 90% of estradiol is solubilized in the solubilizing agent.
  • This pushes the infringement analysis toward analytical measurement of solubilization state (typically based on solubility in the vehicle, partitioning, filtration-based separation, or other assay methods tied to “solubilized” vs “undissolved”).

2) Progesterone must be “suspended,” not solubilized (in claim 1)

  • Claim 1’s structure is specific: estradiol solubilized; progesterone suspended.
  • If a competitor achieves a formulation where progesterone is also fully solubilized in the same solubilizer, that may avoid claim 1 literally (even if the solubilizer is chemically the same and estradiol solubilization is ≥90%).

3) “Uniformly dispersed” ties to a physical distribution constraint

  • Competitors that use stratified systems, layered pellets, or non-uniform mixing may face risk depending on how “uniformly dispersed” is interpreted.

4) The solubilizing agent must be limited to C6-C12 fatty acid ester triglycerides

  • The solubilizer is constrained to mono-, di-, and triglycerides containing an ester of a C6-C12 fatty acid.
  • That excludes many common estradiol softgel vehicles that use longer-chain triglycerides or different excipient classes, unless they fall within the C6-C12 fatty acid ester definition.

5) “At least one of mono-, di-, and triglycerides” allows partial coverage

  • The claim is satisfied if the vehicle includes one or more of those triglyceride classes within the C6-C12 ester constraint, not necessarily all three.

Which dependent claims materially expand or narrow coverage?

Claim 2: “partially solubilized progesterone”

  • Adds an alternative distribution requirement: progesterone can be partially solubilized, with the partially solubilized progesterone still solubilized in the solubilizing agent.
  • This is an important scope adjustment because it can cover formulations where progesterone is not purely suspended but is split between soluble and insoluble fractions.

Claim 3 / 8 / 13: gelatin capsule dosage form

  • Adds a dosage form constraint.
  • If a competitor uses a tablet, softgel, liquid-filled capsule, spray-dried dispersion, or an oral film, claims 3/8/13 would not be met, but claim 1/6/11 could still be asserted if the dosage form limitation is not required for the asserted claim.

Claim 4 / 9 / 14: dosage-strength floor for each steroid

  • Estradiol: at least ~0.125 mg
  • Progesterone: at least ~25 mg
  • This narrows to clinically relevant strength presentations.

Claim 5 / 10 / 15: progesterone:estradiol ratio set points

Ratios explicitly listed:

  • 24:1, 25:1, 96:1, 100:1, 192:1, 200:1

This is a hard numeric fence if the court construes it literally. If a competitor uses a ratio outside those enumerated values (and no range is claimed), the dependent claims may not read. The independent claims (1 and 6 and 11) do not include the ratio, so the ratio may matter only for dependent-claim infringement.


What does claim 6 add: does it create a “stability moat”?

Claim 6 builds on claim 1’s composition limitations but adds a specific physical stability endpoint:

  • Estradiol does not precipitate for at least 14 days.

This can be a major enforcement lever because it creates an experimentally testable condition. A generic or reformulated product could attempt to avoid claim 6 by:

  • changing vehicle composition slightly while staying within or outside the C6-C12 lipid definition, or
  • changing processing and particle size/distribution such that precipitation occurs sooner in the relevant test conditions (which would be antithetical to the claim, but the real risk is the converse: evidence that precipitation does not occur for ≥14 days).

Claim 6 also contains a redundant structure statement:

  • estradiol and suspended progesterone are present in the solubilizing agent and uniformly dispersed
  • at least about 90% estradiol solubilized
  • and estradiol does not precipitate for at least 14 days

Practically, claim 6 is more restrictive than claim 1 and will often be easier to distinguish through stability testing.


What does claim 11 cover: method-of-use risk is tied to the “with a uterus” population

Claim 11 claims a method of treating menopause symptoms in a woman with a uterus by administering the claimed composition.

This is a regulatory-relevant population limitation:

  • “with a uterus” aligns with the clinical standard that estrogen therapy requires adequate progestogen exposure to address endometrial hyperplasia risk.
  • A product labeled for women without a uterus (e.g., after hysterectomy) could try to argue no infringement of a “woman with a uterus” method claim if the labeling and use support no such indication.

The method claim mirrors the composition limitations:

  • solubilized estradiol
  • suspended progesterone
  • both in solubilizing agent, uniformly dispersed
  • ≥90% estradiol solubilized
  • solubilizing agent has mono-/di-/triglycerides with C6-C12 fatty acid esters

Dependent claim 12 adds partially solubilized progesterone; 13 adds gelatin capsule; 14 adds dosage-strength floor; 15 adds ratio.


What are the key claim-limiting terms that drive validity and infringement?

Solubilizing agent chemistry: C6-C12 fatty acid esters

This is likely the most “technical” fence. In portfolio enforcement, challengers commonly pivot to:

  • whether the competitor uses triglycerides derived from fatty acids outside C6-C12
  • whether the excipient is a “mono/di/triglyceride containing an ester of a C6-C12 fatty acid” or a mixture containing outside-chain esters
  • whether the solubilizer includes additives that change the classification or effective solubilizing agent composition

Estradiol “≥90% solubilized”

This is a quantitative functional limitation. It can be attacked through:

  • different analytical definitions of “solubilized”
  • different test conditions and endpoints
  • batch-to-batch variability

For infringement, the plaintiff needs a measurement methodology consistent with the patent’s disclosure and claim interpretation.

Progesterone “suspended” vs “partially solubilized”

This split can produce a binary infringement boundary between:

  • formulations where progesterone is undissolved suspended particles in the vehicle, and
  • formulations where progesterone is dissolved (fully or partially) under the claim structure.

Uniform dispersion

This often becomes a question of how the courts construe the property and whether it is met under the accused manufacturing.

Stability: “no precipitate for at least 14 days”

This adds a litigation-grade performance criterion. It is enforceable if the test conditions are anchored to the patent and the accused product is shown to behave the same.


How does this patent likely relate to the broader estradiol/progesterone oral formulation landscape?

US drug families in this space usually cluster around:

  • vehicle design for estradiol solubilization and precipitation control
  • oral delivery systems (capsules/softgels, lipid-based formulations)
  • combination dosing strategies for estrogen + progesterone/progestins
  • method-of-use claims tailored to uterine status and menopause symptom treatment

US Patent 8,846,649 is positioned specifically at the intersection of:

  • lipid solubilizer chemistry limited to C6-C12 ester mono/di/triglycerides
  • a dual-phase steroid state concept: solubilized estradiol + suspended (or partially solubilized) progesterone
  • quantified solubilization (≥90%) and stability (≥14 days) requirements
  • capsule dosage form limitations in dependent claims
  • and a with-uterus method-of-use.

Where are the “freedom-to-operate” pinch points: what would generics likely change?

Given claim structure, likely design-arounds focus on one or more of these:

  1. Vehicle fatty-acid chain length
    Move to triglycerides/esters that fall outside the C6-C12 definition, while maintaining estradiol exposure.
  2. Solubilization endpoint
    Ensure estradiol does not meet ≥90% solubilized in the claimed solubilizing agent under relevant test.
  3. Progesterone physical state
    Reformulate so progesterone is fully solubilized (avoiding “suspended progesterone” in claim 1 and claim 11) or restructure into a form where “partially solubilized progesterone” is no longer “solubilized in the solubilizing agent” as construed.
  4. Stability behavior
    Increase precipitation propensity to fail the ≥14-day no-precipitation requirement for claim 6.
  5. Dosage form and strength
    Avoid gelatin capsule formats (as to dependent claims 3/8/13) and avoid the listed progesterone:estradiol ratio points (as to dependent claims 5/10/15), and/or adjust strengths (as to dependent claims 4/9/14).
  6. Labeling/indication (method claim constraint)
    For method claims, avoid “woman with a uterus” indication and structure use guidance accordingly.

What would determine how much of the patent estate is actually enforceable in the US?

A full estate analysis requires (a) the patent’s filing/priority history and (b) Orange Book linkage, but those are not provided here. With only the claim text, enforceability assessment is limited to claim scope boundaries.

Still, from the claim set itself, enforceable coverage is best characterized as:

  • Composition-based coverage (claims 1 and 6) that can reach any dosage form unless limited by dependent claims.
  • Method-based coverage (claim 11) that depends on the accused product being used as indicated for women with a uterus, and on the composition limitations being met.

Key Takeaways

  • Independent coverage is tightly defined: estradiol must be ≥90% solubilized in a vehicle containing C6-C12 ester mono-/di-/triglycerides, while progesterone is suspended and uniformly dispersed in that same vehicle.
  • Dependent claims add hard performance and product constraints: no estradiol precipitation for ≥14 days, gelatin capsule format, minimum dose strengths, and specific progesterone:estradiol ratio points.
  • Method claim coverage is population-anchored: the asserted method (claim 11) is for menopause symptoms in women with a uterus, and mirrors the composition limitations.
  • Design-around pressure points are clear: change fatty-acid chain length of the lipid, change solubilization fraction behavior, alter progesterone physical state (suspended vs partially solubilized vs fully solubilized), or engineer precipitation behavior to fail the ≥14-day criterion.

FAQs

1) What solubilizer chemistry could avoid infringement if it uses longer-chain triglycerides?
Avoid vehicles where the mono-/di-/triglycerides are derived from fatty acids outside C6-C12 as required by the “solubilizing agent comprises” limitation.

2) Can a product that fully solubilizes progesterone still infringe claim 1?
Claim 1 requires “suspended progesterone.” A fully solubilized progesterone formulation is positioned to avoid literal claim 1, though claim 2-style “partially solubilized” concepts may still create overlap depending on physical state under claim construction.

3) How do the ratio-dependent claims affect generic launch risk?
Dependent claims list discrete progesterone:estradiol ratios. Launch risk from those dependents is highest when an ANDA/innovator-comparably dosed product matches those ratio points; independent composition claims still apply without the ratio limitation.

4) Does “no estradiol precipitate for at least 14 days” require specific test conditions?
The limitation is testable. If accused product testing under the relevant conditions shows precipitation before 14 days, claim 6 may be avoided.

5) Is the “with a uterus” limitation a strong defense for method-of-use?
It can be, because method claim 11 is confined to treating menopause symptoms in women with a uterus. Labeling and real-world use aligned to different populations can be relevant to infringement of the method claim.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,846,649

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-002 Dec 28, 2021 RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS ⤷  Start Trial
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-001 Oct 28, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,846,649

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2782584 ⤷  Start Trial 301153 Netherlands ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 2021C/558 Belgium ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 122021000080 Germany ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial LUC00245 Luxembourg ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 132021000000197 Italy ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial C202130068 Spain ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 21C1058 France ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.